Cell therapies, in particular, chimeric antigen receptor modified T cells (CAR-T), are showing enormous therapeutic promise, with cancer remission rates over 80 percent. This alone is forcing cell therapy manufacturing companies to develop strategies to build and scale up production at levels never contemplated before.
To read more go to www.bioprocessonline.com/doc/nontraditional-design-concepts-to-accelerate-car-t-processing-0001
